

Attorney Docket No. 25079-Y

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SENN-BILFINGER, Jörg BUHR, Wilm

Serial No.

10/826,337

Examiner: Not yet assigned

Filed:

April 19, 2004

Group Art Unit: Not yet assigned

Title:

PRODRUGS OF IMAZOPYRIDINE DERIVATIVES

## TRANSMITTAL LETTER

The Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) Supplemental Information Disclosure Statement;
- (3) Form PTO-1449 citing seven (7) references; and
- (4) Copies of two (2) non-U.S. patent references.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:

Gary M./Nath

Registration No. 26,965

Jerald L. Meyer

Registration No. 41,194

Sheldon M. McGee

Registration No. 50,454 Customer No. 34375

Date: August <u>25</u>, 2004 **NATH & ASSOCIATES PLLC** 1030 15<sup>TH</sup> Street, NW - 6<sup>th</sup> Floor Washington, D.C. 20005

GMN/SMM\IDS2.TL



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SENN-BILFINGER, Jörg BUHR, Wilm

Serial No. 10/826,337

Examiner: Not yet assigned

Filed:

April 19, 2004

Group Art Unit: Not yet assigned

Title:

PRODRUGS OF IMAZOPYRIDINE DERIVATIVES

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: Only one of items a, b, c, and d must be checked.]

- [x] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [ ] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

- i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. §1.17(p).
- [ ] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.

[] Certification report(e) below; and

- [] a check in the amount as required by§1.17(p).
- [ ] d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.
- [ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[]

[ ]	I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or
[ ]	I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
[ ]	Appropriate certification is attached.
[ x ] f.	If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
[x]g.	Copies of the non-U.S. patent documents are attached herewith with a completed Form PTO-1449.
	OR

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

Copies of the documents are not attached as allowed under CFR 1.98(d)(1).

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

> Respectfully submitted, **NATH & ASSOCIATES PLLC**

Bv:

Registration No. 26,965

Jerald L. Meyer

Registration No. 41,194

Sheldon M. McGee

Registration No. 50,454

Customer No. 34375

Date: August 23, 2004 NATH & ASSOCIATES PLLC 1030 15<sup>TH</sup> Street, NW - 6<sup>th</sup> Floor Washington, D.C. 20005 GMN/SMM\IDS2.

					11						
OIPE					Atty Docket 25079Y	Docket Ser 25079Y 10/					
/ AUG 2 3 200	14 (S) 14 (S) 14	FORM PTO-1449	Applicant SENN-BILFINGER, et al.								
FORM PTO-1449  FORM PTO-1449  U.S. PATENT DOCU					Filing Date April 19, 2004		Group Not y	p Art Un /et assig	it gned		
			U.S. PATE	NT DOCU	MENTS						
Examiner Initial		Document Number	Issue Date		Cla	ss	Sub- Class	Filing Date			
	AA	4,673,679	6/16/1987	<i>F</i>	Augnst, et al.		4	282	5/14/1986		
	AB	5,432,183	7/11/1995	Schulte		51	4	291	11/30/1993		
	AC	6,160,119	12/12/2000	Senn-Bilfinger		54	3	83	11/16/1999		
	AD	6,197,783	3/6/2000	Senn-Bilfinger, et al.		51	4	293	9/24/1999		
	AE	6,436,953	8/20/2002	Senn-Bilfinger		51	4	293	7/19/2000		
	AF										
	AG										
	AH								···		
	Al					<u> </u>					
			FOREIGN PA	TENT DO	CUMENTS						
		Document Number	Date		Country	Clas	ss	Sub- Class	Trans- lation		
	AL	WO 01/072754	10/4/2001		wo				N/A		
	AM										
	AN										
	AO										
	AP										
		OTHER (Inc	luding Author,	Title, Date	, Pertinent Pages, et	c.)					
	Bundgaard, H., Design of Prodrugs, Elsevier Science, pgs. 1-3 (1985).										
	AR		.,	<u> </u>					<u> </u>		
	AS										
	AT										
	AU			<del></del>							
	AV	L									
Examiner						<u>-</u>					
Draw line thi	rough citati	ce considered, whether or not ci tion if not in conformance and no rm with next communication to A	not considered	ince with MPE	P § 609.						